Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Nurix Therapeutics, Inc.

NASDAQ: NRIX · Life Sciences · 11 alerts · CIK 1549595

Share price
$14.73Close, Nov 16
Market cap
$1.61B
Shares outstanding
109.25MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Nurix Therapeutics, Inc. filings on SEC EDGAR ↗

5:06 PM ET Form 4
Insider Selling

Nurix Therapeutics CFO Houte Hans van Sells $74.6K of Stock

Houte Hans van, CFO, sold 4,769 shares of Nurix Therapeutics, Inc. at $15.38 to $16.20 a share (average $15.63) in 2 transactions, worth $74.6K in total on Nov 4, 2026. Shares held after the trade: 42,745 (-3.3%).

Value
$74.6K
Shares
4,769
Average price
$15.63
Role
CFO
Holding change
-3.3%
Trade date
Nov 4, 2026
5:03 PM ET Form 4
Insider Selling

Nurix Therapeutics CLO Christine Ring Sells $432K of Stock

Christine Ring, CLO, sold 16,715 shares of Nurix Therapeutics, Inc. at $25.74 to $26.76 a share (average $25.84) in 3 transactions, worth $432K in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 4,406 (-58.1%).

Value
$432K
Shares
16,715
Average price
$25.84
Role
CLO
Holding change
-58.1%
Trade date
Nov 2, 2026 to Nov 3, 2026
4:02 PM ET 8-K
Deal Termination

Nurix Therapeutics Deal Termination with Sanofi S.A.

Nurix Therapeutics announced that its collaboration partner Sanofi has decided to discontinue the Phase 1 clinical trial and terminate the SAR448272 oral STAT6 degrader program. As a result, Nurix will no longer be eligible for future development, regulatory, or commercial milestone payments and royalties specifically for this program, though other licensed programs under the Sanofi collaboration remain active.

Counterparty
Sanofi S.A.
7:47 PM ET Form 4
Insider Selling

Nurix Therapeutics CFO Houte Hans van Sells $74.5K of Stock

Houte Hans van, CFO, sold 2,834 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $74.5K in total on Oct 30, 2026. Shares held after the trade: 47,514 (-5.6%).

Value
$74.5K
Shares
2,834
Price
$26.28
Role
CFO
Holding change
-5.6%
Trade date
Oct 30, 2026
7:45 PM ET Form 4
Insider Selling

Nurix Therapeutics CLO Christine Ring Sells $104K of Stock

Christine Ring, CLO, sold 3,957 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $104K in total on Oct 30, 2026. Shares held after the trade: 15,335 (-20.5%).

Value
$104K
Shares
3,957
Price
$26.28
Role
CLO
Holding change
-20.5%
Trade date
Oct 30, 2026
7:42 PM ET Form 4
Insider Selling

Nurix Therapeutics CSO Gwenn Hansen Sells $143K of Stock

Gwenn Hansen, CSO, sold 5,409 shares of Nurix Therapeutics, Inc. at $26.28 to $26.80 a share (average $26.42) in 2 transactions, worth $143K in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 123,452 (-1.2%).

Value
$143K
Shares
5,409
Average price
$26.42
Role
CSO
Holding change
-1.2%
Trade date
Oct 30, 2026 to Nov 2, 2026
5:00 PM ET Form 4
Insider Selling

Nurix Therapeutics CSO Gwenn Hansen Sells $36.3K of Stock

Gwenn Hansen, CSO, sold 1,452 shares of Nurix Therapeutics, Inc. at $25.00 a share, worth $36.3K in total on Oct 15, 2026. Shares held after the trade: 117,227 (-1.2%).

Value
$36.3K
Shares
1,452
Price
$25.00
Role
CSO
Holding change
-1.2%
Trade date
Oct 15, 2026
4:12 PM ET Form 4
Insider Selling

Nurix Therapeutics Insider Julia P. Gregory Sells $529K of Stock

Julia P. Gregory sold 22,583 shares of Nurix Therapeutics, Inc. at $23.40 a share, worth $529K in total on Oct 14, 2026. Shares held after the trade: 10,750 (-67.7%).

Value
$529K
Shares
22,583
Price
$23.40
Holding change
-67.7%
Trade date
Oct 14, 2026
6:22 AM ET 10-Q
Financial Results

Nurix Therapeutics Q3 2026 Results: Turns Profitable, Net Income $550M

Nurix Therapeutics reported a significant swing to profitability for the quarter ended August 31, 2026, with net income of $549.8 million compared to a net loss of $86.4 million in the prior year, primarily driven by $653.2 million in license revenue. The company's cash position strengthened significantly to $720.2 million, up from $247.0 million at the end of fiscal 2025.

Key figure
Net income $550M
6:20 AM ET 8-K
Financial Results

Nurix Therapeutics Financial Results

Nurix Therapeutics reported financial results for its fiscal third quarter ended August 31, 2026, highlighting a cash position of $1.1 billion following a $700 million upfront payment from its Roche collaboration. The company achieved several clinical milestones, including dosing the first patient in its Phase 3 DAYBreak CLL-306 trial and advancing its STAT6 degrader into Phase 1 with Sanofi.

Term
Q3 2026

“The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease.”

Arthur T. Sands, M.D., Ph.D., president and chief executive officer
5:21 PM ET Form 4
Insider Selling

Nurix Therapeutics CLO Christine Ring Sells $134K of Stock

Christine Ring, CLO, sold 5,786 shares of Nurix Therapeutics, Inc. at $23.19 a share, worth $134K in total on Oct 2, 2026. Shares held after the trade: 9,110 (-38.8%).

Value
$134K
Shares
5,786
Price
$23.19
Role
CLO
Holding change
-38.8%
Trade date
Oct 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.